UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)UvA-DARE (Digital Academic Repository)Germline SMARCB1 mutation and somatic NF2 mutations in familial multiplemeningiomasChristiaans, I.; Kenter, S.B.; Brink, H.C.; van Os, T.A.M.; Baas, F.; van den Munckhof, P.;Kidd, A.M.J.; Hulsebos, T.J.M.Published in:Journal of Medical GeneticsDOI:10.1136/jmg.2010.082420Link to publicationCitation for published version (APA):Christiaans, I., Kenter, S. B., Brink, H. C., van Os, T. A. M., Baas, F., van den Munckhof, P., ... Hulsebos, T. J.M. (2011). Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. Journalof Medical Genetics, 48(2), 93-97. DOI: 10.1136/jmg.2010.082420General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, statingyour reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Askthe Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,The Netherlands. You will be contacted as soon as possible.Download date: 31 Mar 2017GermlineSMARCB1mutationandsomaticNF2mutationsinfamilialmultiplemeningiomasIChristiaans,1SBKenter,2HCBrink,1TAMvanOs,1FBaas,2PvandenMunckhof,3AMJKidd,4TJMHulsebos2ABSTRACTBackgroundMultiplemeningiomasoccurin<10%ofmeningiomapatients.Theirdevelopmentmaybecausedbythepresenceofapredisposinggermlinemutationintheneuroﬁbromatosistype2(NF2)gene.Thepredisposinggeneinpatientswithnon-NF2associatedmultiplemeningiomasremainstobeidentiﬁed.Recently,SMARCB1wasreportedtobeapotentialpredisposinggeneformultiplemeningiomasinafamilywithschwannomatosisandmultiplemeningiomas.However,involvementofthisgeneinthedevelopmentofthemeningiomaswasnotdemonstrated.ResultsFiveaffectedmembersofalargefamilywithmultiplemeningiomaswereinvestigatedforthepresenceofmutationsinSMARCB1andNF2.Amissensemutationwasidentiﬁedinexon2ofSMARCB1asthecausativegermlinemutationpredisposingtomultiplemeningiomas;furthermore,itwasdemonstratedthat,inaccordancewiththetwo-hithypothesisfortumourigenesis,themutantallelewasretainedandthewild-typeallelelostinallfourinvestigatedmeningiomas.Inaddition,independentsomaticallyacquiredNF2mutationswereidentiﬁedintwomeningiomasofonepatientwithconcomitantlossesofthewild-typeNF2allele.ConclusionItisconcludedthat,analogoustothegeneticeventsinasubsetofschwannomatosisassociatedschwannomas,afour-hitmechanismoftumoursuppressorgeneinactivation,involvingSMARCB1andNF2,mightbeoperativeinfamilialmultiplemeningiomasassociatedmeningiomas.INTRODUCTIONMeningiomasareamongthemostcommonintra-cranialprimarytumours(20%ofallbraintumours),usuallyoccurringasslowlygrowingsporadicsolitarylesions.1Theyalsodevelopinabout50%ofpatientswithneuroﬁbromatosistype2(NF2).ThehallmarkofNF2isthepresenceofbilateralvestibularschwannomas.Schwannomasatotherlocationsarefoundinmorethan50%ofpatients.2e4NF2patientscarryaheterozygousgermlinemutationintheNF2geneandthewild-typecopyofthisgeneisoftenfoundtobelostintheNF2associatedtumours.5e7Multiplemeningiomasoccurin<10%ofpatientswithmeningioma.8ThesemaybeNF2associatedandinthosecasesdevelopastheconsequenceofthepresenceofapredisposingNF2germlinemutation.Non-NF2associatedmultiplemeningi-omasmayoccurassporadicorfamilialcases.ThelimitednumberofmeningiomasoffamilialmultiplemeningiomapatientsinvestigatedthusfardidnotdisplaysomaticorconstitutionalNF2mutations.910ThemultipletumoursofsporadicpatientswerefoundtocarryanidenticalsomaticNF2mutation,whichwasnotpresentintheirconstitutionalDNAs.9e13ThismightbeexplainedbyspreadviathecerebrospinalﬂuidordistantmetastasisofasingletumourorasaconsequenceofmosaicismwithundetectablecontributionoftheNF2mutationtotheconstitutionalDNA.Alter-natively,thenon-NF2sporadicandfamilialcasessuggestthatagenedifferentfromNF2isimplicatedinthedevelopmentofnon-NF2associatedmultiplemeningiomas.Thiscontentionissupportedbyanearlierlinkagestudyinafamilywithmeningiomasinwhicha15cMregionaroundandincludingNF2wasexcludedfromharbouringthemeningiomapredisposinggene.14SMARCB1isapredisposinggeneinschwanno-matosis,whichischaracterisedbythepresenceofmultipleschwannomasintheabsenceofvestibularschwannomas.Thegeneisinvolvedinabout30e40%ofthefamilialcases,butinnomorethan10%ofthesporadiccases.Intheschwannomasofthesepatients,thewild-typecopyofSMARCB1isfoundtobeinactivated,usuallybydeletion.Inaddition,somaticallyacquiredNF2mutationshavebeenfoundinschwannomasofpatientswithagermlineSMARCB1mutation.15e18WewonderedwhetherSMARCB1mightbeapredisposinggeneinmultiplemeningiomasaswell.SupportforthiscandidacyisgivenbythelocationofSMARCB1,whichisproximaltomarkerD22S1,thatisoutsidetheregionexcludedbylinkageanalysis.14Furthermore,somaticSMARCB1mutationshavebeenshowntooccurinsporadicmeningiomas,albeitatlowfrequency,thatis<3%oftumours.19e21EvidencefortheinvolvementofSMARCB1inmultiplemeningiomaswasrecentlyreportedbyBaccietal,22whoshowedtheinheri-tanceofagermlineSMARCB1mutationinafamilywithschwannomatosisandmultiplemeningiomas.However,themutationalstatusofSMARCB1(andofNF2)inthemeningiomasofthepatientswasnotclariﬁed.Inanotherrecentstudy,nogermlineSMARCB1mutationcouldbedetectedin47patientswithmultiplemeningiomas,includingeightfamilialcases.23Inthisstudy,weinvestigatedalargefamilywiththreemembersaffectedbymultiplemeningiomasandtwowithasinglemeningioma.WeidentiﬁedthecausativegermlineSMARCB1mutationsegre-gatingwith(multiple)meningiomasinthisfamilyanddemonstratedinactivationbydeletionofthewild-typecopyofSMARCB1andadditionalbi-allelic1DepartmentofClinicalGenetics,AcademicMedicalCenter,Amsterdam,TheNetherlands2DepartmentofNeurogenetics,AcademicMedicalCenter,Amsterdam,TheNetherlands3DepartmentofNeurosurgery,AcademicMedicalCenter,Amsterdam,TheNetherlands4CanterburyHealthLaboratories,Christchurch,NewZealandCorrespondencetoDrTheoJMHulsebos,DepartmentofNeurogenetics,AcademicMedicalCenter,RoomK2-216,Meibergdreef9,Amsterdam1105AZ,TheNetherlands;t.j.hulsebos@amc.uva.nlReceived29June2010Revised12August2010Accepted23August2010PublishedOnlineFirst7October2010JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242093Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from andindependentinactivationofNF2inmeningiomasofthepatients.PATIENTSANDMETHODSPatientsInformedconsentwasobtainedfromallfamilymembersforusingtheirbodymaterials.Theproband(III-6inﬁgure1)wasreferredtoouroutpatientclinicwithasuspecteddiagnosisofNF2becauseofmultiplemeningiomas.Attheageof34yearsshepresentedwithepilepsy.CTofthebrainshowedthreeextra-axiallesionsalongthefalxcerebri,whichweresuspectedofbeingmeningiomas.Twolesionswereresectedandpathologicalexaminationconﬁrmedthediagnosisofmeningioma.Attheageof51years,ourprobanddevelopedsensoryproblemsandparaplegiaofthelegs.MRIofthebrainandspinalcordshowedanintraduralextramedullarylesionatthoraciclevel(T)7,suspectedofbeingameningioma.Thelesionwasremovedandturnedouttobeapsammomatousmeningioma,WHOgradeI.Herfamilyhistoryrevealedatwinsister(III-7inﬁgure1)withachestwallschwannomaatage37.Atage49,shedevelopedepilepsyandbrainMRIshowedmultipleextra-axiallesions,whichwereonhistologytransi-tional/mixedmeningiomasgradeI.SheunderwentadditionalsurgeryforaspinalﬁbroblasticmeningiomaatT4,multipleschwannomasofthechestwallandelbow,andwasdiagnosedwithmultiplespinallesionssuspectedofbeingschwannomas.Thefatherofthesetwinsistersdiedatage63fromcoronaryarterydisease.Twoofhis10siblingshadbeenundergonesurgeryformeningioma.Anuncleofourproband(II-6inﬁgure1)developedleft-sideddeafnesscausedbyacerebellopontineanglemass,suspectedofbeingavestibularschwannoma,atage56.Atage64,aspinalﬁbroblasticmeningiomaatT1wasremoved;morerecently,atage77,hedevelopedgaitdifﬁcultiesandMRIshowedmultiplespinalintraduralextramedullarylesions,suspectedofbeingmeningiomas.Anauntofourproband(II-9inﬁgure1)underwentsurgeryonaspinalpsammomatousmeningiomaatT10atage53.AﬁbrousmeningiomaatT6wasremovedfromthespinalcordofherdaughter(III-1inﬁgure1)attheageof40years.Noneoftheaffectedfamilymembershadneuroﬁbromas,café-au-laitspotsorfreckling.Theirclinicalcharacteristicsaresummarisedintable1.DNAandRNAsamplesAfrozentissuesampleofabrainmeningiomaM1ofpatientIII-6andformalinﬁxed,parafﬁnembedded(FFPE)tissuesamplesofonemeningiomaeachofpatientsII-6,II-9,andIII-1,andthebrainandspinalcordmeningiomas(M1,M2)ofpatientIII-6,wereavailableformolecularanalysis.DNAwasextractedandpuriﬁedfrombloodsamplesandthetumourtissuesamplesaccordingtostandardmethods.DNAextractedfromthemeningiomaofpatientII-9wastooheavilydegradedforreliablemolecularanalyses.TotalRNAwasextractedandpuriﬁedfromanotherpartofthefrozentissuesampleofmeningiomaM1ofpatientIII-6usingTRIzolLSReagentaccordingtotheprotocolofthemanufacturer(Invitrogen,Leek,TheNetherlands).Onemicro-gramoftotalRNAwasusedtosynthesisecDNAwithrandomprimingaccordingtostandardmethods.MicrosatelliteanalysisGenotypingoffamilymembersandlossofheterozygosity(LOH)analysisoftumourswereperformedbyusingthechromosome22-speciﬁcmicrosatellitemarkersoftheABIPrismLinkageMappingSetversion2.5-HD5andadditionalmarkerD22S929.PrimersequencesforthelattermarkerweretakenfromLegoixetal.24DatawereanalysedwithGenemappersoftwareversion4.0.(AppliedBiosystems,FosterCity,California,USA).MutationanalysisSMARCB1andNF2weresequencedbyusinggenomicorcDNAassubstrateforampliﬁcationbyPCR.PrimersequencesformutationanalysisoftheSMARCB1andNF2exonshavebeenpublishedpreviously.15Forimprovedperformance,someSMARCB1primerswerenewlydesigned(sequencesavailableonrequest).IndegradedDNAextractedfromFFPEmaterial,theSMARCB1exon2segmentharbouringthemissensemutationwassequencedbyusingforwardprimer59eCCCTTATAATGAGCCTTCTTGCTe39andreverseprimer59-TCTTCCACAGTGGCTAGTCG-39,gener-atingaPCRproductof116bp.ThecDNAproductfrommeningiomaM1ofpatientIII-6wassequencedbyusingforwardprimer59-GACGGCGAGTTC-TACAT-39inexon1andreverseprimer59-TTTTACCATGT-GACGATGCAA-39atthe39-endofexon2,generatingaPCRproductop148bp.AllsequencereactionswereperformedusingABIBigDyev3.1chemistry,andtheproductsweresequencedwithanABI3730capillarysystem(AppliedBiosystems).SequenceswereanalysedwithCodonCodeAligner(CodonCodeCorp,Dedham,Massachusetts,USA).TheHomoloGeneprograminPubMedwasusedtoperformaminoacidsequencealignments(http://www.ncbi.nlm.nih.gov/pubmed).ThePolyPhenandSIFTprogramswereusedtopredicttheimpactofaminoacidsubstitutionsonproteinfunctionandstructure(http://genetics.bwh.harvard.edu/pphandhttp://sift.jcvi.org,respectively).RESULTSSequencingofthenineexonsofSMARCB1inconstitutionalDNAofprobandIII-6revealedamissensemutationinexon2,Figure1GenotypingofSMARCB1andﬂankingmicrosatellitemarkersinconstitutionalblood(B)andcorrespondingmeningioma(M)DNAofaffectedmembersinamultiplemeningiomasfamily.Patientswith(multiple)meningiomasaremarkedbybluesymbols.Diamondsymbolsindicatefamilymemberswithinsufﬁcientclinicaldetails(underclinicalandmolecularinvestigation).Thewild-typeandmutantalleleofSMARCB1areindicatedbyCandT,respectively.MarkerallelesaregivenbythelengthoftheirPCRproducts(bp).94JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.082420Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from c.143C/T,P48L(ﬁgure2),whichalsoprovedtobepresentinconstitutionalDNAoftheotheraffectedfamilymembers(III-7,II-6,II-9,andIII-1).Themutationwasnotfoundinconstitu-tionalDNAofmorethan100controlindividuals.TheprolineresiduethatisreplacedbyleucineintheresultingSMARCB1proteinisevolutionarilyconservedacrossallspeciesforwhichsequenceinformationisavailable(datanotshown).InsilicoanalyseswiththePolyphenandSIFTprogramspredictedthattheaminoacidsubstitutionaffectsSMARCB1proteinfunctionandisprobablydamaging.Thefourmeningiomasthatwereavailableformolecularanalysisallshowedlossofthewild-typeCallele,asdemon-stratedinﬁgure2forthebrain(M1)andspinalcord(M2)meningiomaoftheproband(III-6).Inaccordancewiththis,genotypingwithﬂankingmarkersrevealedretentionofthechromosome22segmentcontainingthemutantT-alleleintheinvestigatedtumours,asexempliﬁedinﬁgure2formarkerD22S1174.Thedataaresummarisedinﬁgure1.ToinvestigatewhethertheretainedSMARCB1allelewastranscribed,weextractedtotalRNAfromfrozentissueofmeningiomaM1andreversetranscribeditintocDNA.ThecDNAsequencedemonstratesthatastablemRNAistranscribedfromtheretainedmutantallele(ﬁgure2).Schwannomatosisassociatedschwannomasharboursomati-callyacquiredNF2mutations.Consideringtheapparentanalogywithschwannomatosis,wewonderedwhetherthesemutationsmightalsobepresentinthemeningiomasofthefamilyunderstudy.AlthoughattemptsweremadetosequenceNF2inallavailablemeningiomas,reliablesequencescouldonlybederivedfromthefrozentumourM1andthefreshlyﬁxedtumourM2,bothofprobandIII-6.Wefoundamissensemutationinexon4ofmeningiomaM1(c.422T/G,p.L141R)andanonsensemutationinexon8(c.773G/A,p.W258X)ofmeningiomaM2,bothbeingabsentinthecorrespondingconstitutionalDNAofthepatient(ﬁgure3).Theleucineresidueatposition141isevolutionarilyconserved(datanotshown).ThePolyphenandSIFTprogramspredictedthattheaminoacidsubstitutioncausedbythemissensemutationaffectsNF2proteinfunctionandisprobablydamaging.Thesequencerecordingsindicatelossofthewild-typealleleinbothtumours.Thisissubstanti-atedbyLOHanalysiswiththeintragenicNF2markerD22S929,whichshowsconsiderablelossofthe132bpalleleintumourM1aswellastumourM2(ﬁgure3).Finally,wesequencedallexonsoftheNF2geneinconstitutionalDNAoftheaffectedfamilymembers(III-6,III-7,II-6,II-9,III-1),butdidnotdetectanydeviationfromthewild-typesequence.Table1ClinicalcharacteristicsofaffectedfamilymembersPatientSex(M/F)Age(years)atdiagnosisPresentingsymptomMeningiomas(n,location)Schwannomas(n,location)III-6F34Epilepsy3cranial,1spinaleIII-7F37ChestwallmassMultiplecranial,1spinalMultiplechestwall,multiplespinal,1elbowII-6M56DeafnessMultiplespinal1vestibularII-9F53Paresislegs1spinaleIII-1F40Sensoryproblemslegs1spinaleFigure2Sequenceanalysisofpartofexon2ofSMARCB1andlossofheterozygosity(LOH)analysiswithmarkerD22S1174inbloodandmeningiomaDNAsofpatientIII-6.Left:presenceofthemutantTalleleinconstitutionalblood(B)DNAandconsiderablelossofthewild-typeCalleleingenomicandcDNAofmeningiomaM1andingenomicDNAofmeningiomaM2.Right:PresenceoftwoallelesofmarkerD22S1174inbloodDNAandconsiderablelossofthe145bpallele,markedbyarrow,inmeningiomaM1andM2DNA.JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242095Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from Inaddition,weperformedmultipleligationdependentprobeampliﬁcation(MLPA)analysisoftheNF2geneinconstitutionalDNAofpatientIII-7.However,thisanalysisdidnotrevealanydeletionsorduplications.DISCUSSIONWeidentiﬁedthegermlinemutationc.143C/TinSMARCB1thatmostprobablypredisposestothedevelopmentofmultiplemeningiomas.Themutationsegregateswiththepresenceof(multiple)meningiomasinthisfamilyand,inaccordancewithKnudsons’two-hithypothesisfortumourigenesis,25remainsinthefourinvestigatedmeningiomas,eachwithlossofthewild-typeSMARCB1allelebyLOH(ﬁgure2).Thecausativenatureofthismissensemutationmaybeinferredfromourinsilicoanalyses,whichdemonstratedthattheprolineresidueatposi-tion48isevolutionaryconservedandthatthechangetoleucineaffectsSMARCB1proteinfunctionandisprobablydamaging.Theimportanceofprolineatthatpositionisfurthermoresupportedbytheﬁndingofanothermissensemutationcausingitsreplacement(c.142C/T,p.P48S)inamalignantrhabdoidtumourofthekidney.26AnothermissensemutationintheSMARCB1gene,c.92A/T,p.E31V,wasrecentlyidentiﬁedasthepredisposinggeneticeventinafamilywithschwannomatosisandmultiplemeningioma.22RNAstudiesinwholebloodoftwopatientsinthisfamilydemonstratedabsenceoftranscriptsfromthemutantSMARCB1allele.We,however,detectedastabletranscriptderivedfromthemutantSMARCB1allelethatwasretainedinmeningiomaM1ofpatientIII-6(ﬁgure2).Accord-ingly,wefounduniformstainingofnucleiwithaSMARCB1antibody(anti-BAF47)inallfourmeningiomas,suggestingthatanintactSMARCB1proteinwasformed(datanotshown).Thepresenceofaleftsidedcerebellopontineanglemass,probablyavestibularschwannoma,inpatientII-6andofmultipleschwannomasinpatientIII-7suggestthattheSMARCB1mutationinthisfamilymaypredisposetothedevelopmentofschwannomasaswell.However,thevestibularschwannomawasdiagnosedatage56andsuchasporadicunilateraltumourisnotuncommonatthatageinthegeneralpopulation.27Unfortunately,theschwannomaswerenotavail-abletofurtherinvestigatethepossibleinvolvementofSMARCB1.Aschwannomaanalysedinthefamilywithschwannomatosisandmultiplemeningiomasindeeddisplayedbi-allelicinactivationofSMARCB1.22Twootherschwannoma-tosisfamilies,eachwithonepatientdevelopingoneortwomeningiomas,havebeenreported.However,thestatusofSMARCB1inthesetumourswasnotinvestigated.16172829Consideringthefrequentoccurrenceofmeningiomasinthegeneralpopulation,1itcannotbeexcludedthattheirassociationwithschwannomatosisinthelatterfamilieswascoincidental.Ontheotherhand,themissensemutationinSMARCB1inourfamily,affectingaminoacidresidue48,andmostprobablyalsointhefamilypresentedbyBaccietal,22affectingnearbyaminoacidresidue31,clearlypredisposetothedevelopmentofmultiplemeningiomas.Therefore,itispossiblethattheprefer-enceformeningiomadevelopmentis,atleastinpart,deter-minedbytypeandlocationoftheSMARCB1mutation.Alternatively,theco-occurrenceofschwannomasandmeningi-omasinsomeSMARCB1familiesandthesoleoccurrenceofschwannomasinmostotherSMARCB1familiesmaypointtotheexistenceofmodifyinggenessegregatinginthesefamiliesandaffectingthephenotypicexpressionoftheSMARCB1mutation.Ourﬁnding,andthatofBaccietal,22thatmeningi-omasarepartoftheschwannomatosistumourspectrummayrequirethediagnosticcriteriaforthisdiseasebereconsidered.FurtherinvestigationofthepossibleassociationoftypeandlocationoftheSMARCB1mutationandthedevelopmentofmultiplemeningiomasandofpossiblemodifyingfactorswillrequiretheidentiﬁcationandclinicalevaluationofadditionalcarriersofthemutatedgeneinourfamilyandinothermultiplemeningiomaspatientsandfamilies.WeidentiﬁedadditionalindependentsomaticmutationsintheNF2geneinthebrain(M1)andspinalcord(M2)meningi-omasofpatientIII-6(ﬁgure3).Themissensemutationinexon4inmeningiomaM1causedreplacementoftheevolutionaryconservedleucineresidueatposition141intheNF2proteinanditschangeintoarginineaffects,accordingtotheinsilicoanal-yses,proteinfunctionandisprobablydamaging.Theimpor-tanceofleucineatposition141isfurthermoresupportedbytheﬁndingofanothermissensemutationcausingitsreplacement(c.422T/C,p.L141P),whichwasreportedasaconstitutionalNF2mutationinapatientwithbilateralschwannomas.30Theexon8mutationinmeningiomaM2isatypicalNF2nonsensemutation,causingtruncationoftheprotein.30InaccordancewithKnudsons’two-hitmodel,lossofthewild-typecopyofNF2byLOHoccurredinbothtumours.25Theﬁndingoftwocausativehits(NF2mutationanddeletion)inthesemeningi-omasandourfailuretodetectaconstitutionalNF2mutationordeletionintheaffectedfamilymembersstronglyargueagainstthisgeneasbeingthemultiplemeningiomapredisposinggeneinthisfamily.Summarisingourdata,weconcludethat,analogoustothegeneticeventsinasubsetofschwannomatosisassociatedschwannomas,16e18afour-hitmechanismoftumoursuppressorgeneinactivation,involvingSMARCB1andNF2,mightalsobeoperativeinfamilialmultiplemeningiomasassociatedmenin-giomas.Inarecentstudy,nogermlineSMARCB1mutationsweredetectedin47patientswithmultiplemeningiomas,includingeightfamilialcases.23GermlineSMARCB1mutationsareinfrequentlyfoundinsporadicschwannomatosispatientsFigure3Sequenceanalysisofpartofexons4and8ofNF2andlossofheterozygosity(LOH)analysiswithmarkerD22S929inbloodandmeningiomaofpatientIII-6.Left:presenceofthemutantGalleleinexon4inmeningiomaM1DNAandthemutantAalleleinexon8inmeningiomaM2DNA,butabsenceofthesemutantallelesinconstitutionalblood(B)DNA.Right:PresenceoftwoallelesofmarkerD22S929inbloodDNAandconsiderablelossofthe132bpallele,markedbyarrow,inmeningiomaM1andM2DNA.96JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.082420Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from (<10%ofcases).Itispossiblethat,asinfamilialschwannoma-tosis(30e40%ofcases),SMARCB1involvementismorefrequentinfamilialmultiplemeningiomas.Alternatively,othergenesmightbeimplicatedaspredisposinggeneticfactorsinbothdiseases.AcknowledgementsWethankthefamilymembersfortheirparticipationinthisstudy.WeareindebtedtoDrDTroost(NeuropathologyDepartment,AcademicMedicalCenter,Amsterdam),DrMGHavenith(PathologyDepartment,IsalaClinics,Zwolle),DStomphorst(PathologyDepartment,LeidenUniversityMedicalCenter,Leiden),andMWaaijer(PathologyDepartment,MedicalCenterAlkmaar,Alkmaar)forprovidingtumourmaterials.CompetinginterestsNone.PatientconsentObtained.ProvenanceandpeerreviewNotcommissioned;externallypeerreviewed.REFERENCES1.ClausEB,BondyML,SchildkrautJM,WiemelsJL,WrenschM,BlackPM.Epidemiologyofintracranialmeningioma.Neurosurgery2005;57:1088e95.2.EvansDG,HusonSM,DonnaiD,NearyW,BlairV,TeareD,NewtonV,StrachanT,RamsdenR,HarrisR.Ageneticstudyoftype2neuroﬁbromatosisintheUnitedKingdom.I.Prevalence,mutationrate,ﬁtness,andconﬁrmationofmaternaltransmissioneffectonseverity.JMedGenet1992;29:841e6.3.ParryDM,EldridgeR,Kaiser-KupferMI,BouzasEA,PikusA,PatronasN.Neuroﬁbromatosis2(NF2):clinicalcharacteristicsof63affectedindividualsandclinicalevidenceforheterogeneity.AmJMedGenet1994;52:450e61.4.MautnerVF,LindenauM,BaserME,HazimW,TatagibaM,HaaseW,SamiiM,WaisR,PulstSM.Theneuroimagingandclinicalspectrumofneuroﬁbromatosis2.Neurosurgery1996;38:880e5.5.BijlsmaEK,MerelP,BoschDA,WesterveldA,DelattreO,ThomasG,HulsebosTJ.AnalysisofmutationsintheSCHgeneinschwannomas.GenesChromosomesCancer1994;11:7e14.6.Me´relP,Hoang-XuanK,SansonM,BijlsmaE,RouleauG,Laurent-PuigP,PulstS,BaserM,LenoirG,SterkersJM,etal.Screeningforgerm-linemutationsintheNF2gene.GenesChromosomesCancer1995;12:117e27.7.LamszusK,VahldiekF,MautnerVF,SchichorC,TonnJ,StavrouD,FillbrandtR,WestphalM,KluweL.Alleliclossesinneuroﬁbromatosis2-associatedmeningiomas.JNeuropatholExpNeurol2000;59:504e12.8.NahserHC,GroteW,Lo¨hrE,GerhardL.Multiplemeningiomas.Clinicalandcomputertomographicobservations.Neuroradiology1981;21:259e63.9.HeinrichB,HartmannC,Stemmer-RachamimovAO,LouisDN,MacCollinM.Multiplemeningiomas:investigatingthemolecularbasisofsporadicandfamilialforms.IntJCancer2003;103:483e8.10.EvansDG,WatsonC,KingA,WallaceAJ,BaserME.Multiplemeningiomas:differentialinvolvementoftheNF2geneinchildrenandadults.JMedGenet2005;42:45e8.11.StanglAP,WellenreutherR,LenartzD,KrausJA,MenonAG,SchrammJ,WiestlerOD,vonDeimlingA.Clonalityofmultiplemeningiomas.JNeurosurg1997;86:853e8.12.ZhuJJ,MaruyamaT,JacobyLB,HermanJG,GusellaJF,BlackPM,WuJK.Clonalanalysisofacaseofmultiplemeningiomasusingmultiplemoleculargeneticapproaches:pathologycasereport.Neurosurgery1999;45:409e16.13.EcksteinO,Stemmer-RachamimovA,NunesF,HochD,OjemannR,MacCollinM.MultiplemeningiomasinbrainandlungduetoacquiredmutationoftheNF2gene.Neurology2004;62:1904e5.14.PulstSM,RouleauGA,MarineauC,FainP,SiebJP.Familialmeningiomaisnotallelictoneuroﬁbromatosis2.Neurology,1993;43:2096e8.15.HulsebosTJ,PlompAS,WoltermanRA,Robanus-MaandagEC,BaasF,WesselingP.GermlinemutationofINI1/SMARCB1infamilialschwannomatosis.AmJHumGenet2007;80:805e10.16.BoydC,SmithMJ,KluweL,BaloghA,MaccollinM,PlotkinSR.AlterationsintheSMARCB1(INI1)tumorsuppressorgeneinfamilialschwannomatosis.ClinGenet2008;74:358e66.17.HadﬁeldKD,NewmanWG,BowersNL,WallaceA,BolgerC,ColleyA,McCannE,TrumpD,PrescottT,EvansDG.MolecularcharacterisationofSMARCB1andNF2infamilialandsporadicschwannomatosis.JMedGenet2008;45:332e9.18.SestiniR,BacciC,ProvenzanoA,GenuardiM,PapiL.Evidenceofafour-hitmechanisminvolvingSMARCB1andNF2inschwannomatosis-associatedschwannomas.HumMutat2008;29:227e31.19.BruderCE,DumanskiJP,KedraD.ThemouseorthologofthehumanSMARCB1geneencodestwospliceforms.BiochemBiophysResCommun1999;257:886e90.20.SchmitzU,MuellerW,WeberM,Se´venetN,DelattreO,vonDeimlingA.INI1mutationsinmeningiomasatapotentialhotspotinexon9.BrJCancer2001;84:199e201.21.RieskeP,ZakrzewskaM,PiaskowskiS,Jasko´lskiD,SikorskaB,PapierzW,ZakrzewskiK,LiberskiPP.MolecularheterogeneityofmeningiomawithINI1mutation.MolPathol2003;56:299e301.22.BacciC,SestiniR,ProvenzanoA,PaganiniI,ManciniI,PorﬁrioB,VivarelliR,GenuardiM,PapiL.SchwannomatosisassociatedwithmultiplemeningiomasduetoafamilialSMARCB1mutation.Neurogenetics2010;11:73e80.23.HadﬁeldKD,SmithMJ,TrumpD,NewmanWG,EvansDG.SMARCB1mutationsarenotacommoncauseofmultiplemeningiomas.JMedGenet2010;47:567e8.24.LegoixP,LegrandMF,OllagnonE,LenoirG,ThomasG,Zucman-RossiJ.Characterisationof16polymorphicmarkersintheNF2gene:applicationtohemizygositydetection.HumMutat1999;13:290e3.25.KnudsonAGJr.Mutationandcancer:statisticalstudyofretinoblastoma.ProcNatlAcadSciUSA1971;68:820e3.26.Se´venetN,Lellouch-TubianaA,SchoﬁeldD,Hoang-XuanK,GesslerM,BirnbaumD,JeanpierreC,JouvetA,DelattreO.SpectrumofhSNF5/INI1somaticmutationsinhumancancerandgenotype-phenotypecorrelations.HumMolGenet1999;8:2359e68.27.BaserME,FriedmanJM,EvansDG.Increasingthespeciﬁcityofdiagnosticcriteriaforschwannomatosis.Neurology2006;66:730e2.28.EvansDG,MasonS,HusonSM,PonderM,HardingAE,StrachanT.Spinalandcutaneousschwannomatosisisavariantformoftype2neuroﬁbromatosis:aclinicalandmolecularstudy.JNeurolNeurosurgPsychiatry1997;62:361e6.29.MacCollinM,WillettC,HeinrichB,JacobyLB,AciernoJSJr,PerryA,LouisDN.Familialschwannomatosis:exclusionoftheNF2locusasthegermlineevent.Neurology2003;60:1968e74.30.AhronowitzI,XinW,KielyR,SimsK,MacCollinM,NunesFP.MutationalspectrumoftheNF2gene:ameta-analysisof12yearsofresearchanddiagnosticlaboratoryﬁndings.HumMutat2007;28:1e12.JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242097Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from doi: 10.1136/jmg.2010.0824202010 2011 48: 93-97 originally published online October 7,J Med Genet(cid:160)I Christiaans, S B Kenter, H C Brink, et al.(cid:160)meningiomas mutations in familial multipleNF2 mutation and somatic SMARCB1Germline  http://jmg.bmj.com/content/48/2/93.full.htmlUpdated information and services can be found at: These include:References http://jmg.bmj.com/content/48/2/93.full.html#related-urlsArticle cited in: (cid:160) http://jmg.bmj.com/content/48/2/93.full.html#ref-list-1This article cites 30 articles, 12 of which can be accessed free at:serviceEmail alertingthe box at the top right corner of the online article.Receive free email alerts when new articles cite this article. Sign up inCollectionsTopic (1086 articles)Molecular genetics (cid:160) (cid:149) (69 articles)Neurooncology (cid:160) (cid:149) (37 articles)CNS cancer (cid:160) (cid:149)(cid:160)Articles on similar topics can be found in the following collectionsNotes http://group.bmj.com/group/rights-licensing/permissionsTo request permissions go to: http://journals.bmj.com/cgi/reprintformTo order reprints go to: http://group.bmj.com/subscribe/To subscribe to BMJ go to: group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from 